据报科兴生物疫苗於巴西第三期测试通过5成有效率门槛
《华尔街日报》引述消息人士报道,中国科兴生物的新冠病毒疫苗在巴西的第三期临床测试通过50%有效率的门槛,意味着监当地管机构可批准疫苗上市。
巴西是全球首个完成科兴生物疫苗第三期测试的国家,由於疫情在中国基本受控,中国的疫苗开发商不得不在国外进行临床测试。据悉,该疫苗通过50%有效率的门槛,预计最终有效率可媲美其他被证明有效性达95%的新冠疫苗。
一直在为科兴生物疫苗进行测试的巴西Butantan Institute准备在明日宣布疫苗的有效性,之後会将数据提交予巴西及中国的药品监管机构,中国可能会先於巴西批准疫苗。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.